Literature DB >> 17989155

Air travel hypoxemia vs. the hypoxia inhalation test in passengers with COPD.

Paul T Kelly1, Maureen P Swanney, Leigh M Seccombe, Chris Frampton, Matthew J Peters, Lutz Beckert.   

Abstract

BACKGROUND: Limited data are available comparing air travel with the hypoxia inhalation test (HIT) in passengers with COPD. The aim of this study was to assess the predictive capability of the HIT to in-flight hypoxemia in passengers with COPD.
METHODS: Thirteen passengers (seven female passengers) with COPD (mean [+/- SD], FEV(1)/FVC ratio, 44 +/- 17%) volunteered for this study. Respiratory function tests were performed preflight. Pulse oximetry, cabin pressure, and dyspnea were recorded in flight. The HIT and a 6-min walk test were performed postflight. The in-flight oxygenation response was compared to the HIT results and respiratory function parameters.
RESULTS: All subjects flew without the use of oxygen, and no adverse events were recorded in-flight (mean cabin altitude, 2,165 m; altitude range, 1,892 to 2,365 m). Air travel caused significant desaturation (mean preflight oxygen saturation, 95 +/- 1%; mean in-flight oxygen saturation, 86 +/- 4%), which was worsened by activity (nadir pulse oximetric saturation [Spo(2)], 78 +/- 6%). The HIT caused mean desaturation that was comparable to that of air travel (84 +/- 4%). The mean in-flight partial pressure of inspired oxygen (Pio(2)) was higher than the HIT Pio(2) (113 +/- 3 mm Hg vs 107 +/- 1 mm Hg, respectively; p < 0.001). The HIT Spo(2) showed the strongest correlation with in-flight Spo(2) (r = 0.84; p < 0.001).
CONCLUSION: Significant in-flight desaturation can be expected in passengers with COPD. The HIT results compared favorably with the air travel data, with differences explainable by Pio(2) and physical activity. The HIT is the best widely available laboratory test to predict in-flight hypoxemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989155     DOI: 10.1378/chest.07-1483

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Effects of commercial air travel on patients with pulmonary hypertension air travel and pulmonary hypertension.

Authors:  Nareg Roubinian; C Gregory Elliott; Christopher F Barnett; Paul D Blanc; Joan Chen; Teresa De Marco; Hubert Chen
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

2.  Predicting the need for supplemental oxygen during airline flight in patients with chronic pulmonary disease: a comparison of predictive equations and altitude simulation.

Authors:  Ana C Bradi; Marie E Faughnan; Matthew B Stanbrook; Eva Deschenes-Leek; Kenneth R Chapman
Journal:  Can Respir J       Date:  2009 Jul-Aug       Impact factor: 2.409

3.  Pre-flight evaluation of adult patients with cystic fibrosis: a cross-sectional study.

Authors:  Elisabeth Edvardsen; Aina Akerø; Ole Henning Skjønsberg; Bjørn Skrede
Journal:  BMC Res Notes       Date:  2017-02-06

4.  Are pulmonologists well aware of planning safe air travel for patients with COPD? The SAFCOP study.

Authors:  Begüm Ergan; Hüseyin Arıkan; Metin Akgün
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-08-22

5.  BTS Clinical Statement on air travel for passengers with respiratory disease.

Authors:  Robina Kate Coker; Alison Armstrong; Alistair Colin Church; Steve Holmes; Jonathan Naylor; Katharine Pike; Peter Saunders; Kristofer John Spurling; Pamela Vaughn
Journal:  Thorax       Date:  2022-02-28       Impact factor: 9.139

6.  Assessing Patients for Air Travel.

Authors:  Amy L Bellinghausen; Jess Mandel
Journal:  Chest       Date:  2020-11-16       Impact factor: 9.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.